Careers  |  Sign In  |  Register

Expert Discusses Novel Treatment Approach for TP53-Mutant MDS and AML

Raajit K. Rampal, MD, PhD, hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses a recent study on the use of APR-246 for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). APR-246 is a novel agent designed to refold TP53 proteins in patients with TP53 mutations who typically exhibit poor response under current standards of care. Dr. Rampal is planning for a phase 3 randomized trial with standard azacitidine alone versus APR-246 plus azacitidine for MDS patients with TP53 mutations.

Click here to learn more.